Announcements Trials

Browse Landscape

Phase

Phase EARLY_PHASE1 1 Phase 1/2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Recurrence 1 Neuroblastoma 1 Mesothelioma, Malignant 1 Mesothelioma 1 Ganglioneuroblastoma 1

Interventions

Dexamethasone 33 Cyclophosphamide 29 venetoclax 18 fludarabine 18 Lenalidomide 16 Bortezomib 16 Cytarabine 13 pembrolizumab 12 Calcium Dobesilate 12 Carboplatin 11 fludarabine phosphate 10 Rituximab 10 pomalidomide 9 Gemcitabine 9 Nivolumab 8 Azacitidine 7 daratumumab 6 carfilzomib 6 blinatumomab 6 Decitabine 6 Bendamustine Hydrochloride 6 selinexor 5 obinutuzumab 5 ibrutinib 5 Vincristine 5 Temozolomide 5 Methotrexate 5 Etoposide 5 Cisplatin 5 tafasitamab 4

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × Recurrence × Influenza Vaccines × Clear all

NCT07502287 2026-03-30

DUAL-NK-NB

Beijing Biotech

Phase 1/2 Recruiting

Neuroblastoma, Recurrence, Ganglioneuroblastoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡